Urs Spitz News Today

Biosynth, a supplier of critical raw materials to the life science industry, announced that it has acquired VIO Chemicals, a Zurich-based company with leading chemical R&D expertise and a glob ...

The acquisition of multi-kilogram GMP and fill-finish capabilities enables the support of all phases of the product life cycle from discovery to commercialisation.STAAD, Switzerland--(BUSINESS WIRE)--Biosynth, a supplier of critical materials to the life science industry, is pleased to announce the acquisition of Pe...

Critical raw materials supplier Biosynth (Staad, Switzerland) ) recently acquired German company celares, a leader in the development and manufacture of conjugate vaccines and bioconjugate drugs, activated PEGs and polymer-based drug delivery excipients, which will now be offered to the Swiss organisation’s existing pharma and diagnostics customer base, from GMP facilities located in Berlin, Germany. Click to read more...

Addition of UK based peptide and antibody production facilities expands peptides and biologics business in UK and Europe. Biosynth, a supplier of critical raw materials to the life science industry

Trinity said it is selling the business to focus on its core operations in diabetes care, decentralized patient monitoring, and diagnostic solutions.

Rebranding aligns core Biosynth Group members across Complex Chemical and Peptide Manufacturing Services and Catalog Business. Biosynth Carbosynth, vivitide and Pepscan are pleased to announce today

EUCODIS Bioscience, specialists in engineering and developing enzymes for pharma, biotech and applied markets has been acquired by Biosynth Carbosynth, a supplier of critical biological materials to the life science industry. Click to read more...

Addition of Pepscan with its peptide discovery, lead optimization and GMP manufacturing capabilities provides end-to-end offering to Biosynth Carbosynth's peptide customers. Biosynth Carbosynth ("Biosynth")

Global life science industry critical materials supplier Biosynth Carbosynth has acquired Aalto Bio Reagents (Dublin), a leading developer and provider of biological materials to the in-vitro diagnostic (IVD) and vaccine development industry in the field of emerging disease. Click to read more...

Switzerland-based Biosynth Carbosynth is acquiring Aalto Bio to broaden its offering in the in-vitro diagnostic industry.